The TLR7 agonist Imiquimod promote the immunogenicity of mesenchymal stem cells.

ABSTRACT:

Background

Mesenchymal stem cells (MSCs) are considered the best candidate in stem cells therapy due to their multipotent differentiation ability, low expression of co-stimulatory molecules (CD80, CD86, CD34 and HLA-II) and immunosuppression effects on in vivo immune responses. MSCs were now widely used in clinical trials but received no encourage results. The major problem was the fate of engrafted MSCs in vivo could not be defined. Some studies indicated that MSCs could induce immune response and result in the damage and rejection of MSCs. As toll like receptors (TLRs) are important in inducing of immune responses, in this study we study the role of TLR7 in mediating the immune status of MSCs isolated from umbilical cord.

Results

Our results indicated that TLR7 agonist Imi

SUBMITTER: Zhang L 

PROVIDER: S-EPMC4363195 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature